Avalon GloboCare Corp. (NASDAQ:CHGA) Shares Shorted: Short Interest Up 156.5% in September

Posted by Alphonse Anthony on Oct 14th, 2026

Avalon GloboCare Corp. (NASDAQ:CHGA – Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 85,127 shares, a growth of 156.5% from the September 15th total of 33,188 shares. Based on an average trading volume of 3,006,731 shares, the short-interest ratio is presently 0.0 days. Currently, 9.1% of the company’s stock are sold short.

Avalon GloboCare Price Performance

Shares of CHGA stock traded down $0.20 on Wednesday, hitting $1.82. The stock had a trading volume of 92,422 shares, compared to its average volume of 359,417. The business has a 50 day moving average of $3.24 and a 200 day moving average of $5.84. The stock has a market cap of $2.04 million, a price-to-earnings ratio of -0.13 and a beta of -0.08. Avalon GloboCare has a 12-month low of $1.72 and a 12-month high of $47.60.

Avalon GloboCare (NASDAQ:CHGA – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($2.80) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 24th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Read Our Latest Report on CHGA

About Avalon GloboCare

(Get Free Report)

Avalon GloboCare Corp. is a biotechnology company focused on developing cell-based and regenerative medicine technologies. Its work has included cellular immunotherapies, exosome-based products and other platforms intended to support the treatment of cancer and other serious medical conditions.

The company has also pursued activities involving cell and gene therapy development, biobanking and related laboratory services. Avalon GloboCare has described its business as spanning research, product development and potential commercialization through collaborations and strategic partnerships.

Avalon GloboCare was founded in the United States and has historically been associated with operations in New Jersey.